Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Gait Mechanics are Different between Healthy Controls and Patients with Multiple Sclerosis.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Genzyme’s once-daily, oral AUBAGIO® approved in Australia for treatment of relapsing multiple sclerosis
Benign multiple sclerosis: a distinct clinical entity with therapeutic implications.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Contribution of the oligodendrocyte lineage to CNS repair and neurodegenerative pathologies.
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Autoimmunity in visual loss.
RTL therapy for multiple sclerosis: a Phase I clinical study.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate)
Multiple sclerosis: A lifestyle disease?
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)
Interferon in relapsing-remitting multiple sclerosis.

Pages